instruction
stringlengths 22
145
| input
stringclasses 1
value | answer
stringlengths 220
325
| text
stringlengths 382
597
|
|---|---|---|---|
The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Comparison of the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of patient characteristics on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of genetic factors in the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of previous treatments on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The correlation between the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of supportive care in improving the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of concurrent health conditions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd). | The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Elotuzumab+Pomalidomide+Dexamethasone (EPd) from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |